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a b s t r a c t
Acyloxydiene–Fe(CO)3 complexes can act as enzyme-triggered CO-releasing molecules (ET-CORMs).
Their biological activity strongly depends on the mother compound from which they are derived, i.e.
cyclohexenone or cyclohexanedione, and on the position of the ester functionality they harbour. The
present study addresses if the latter characteristic affects CO release, if cytotoxicity of ET-CORMs is
mediated through iron release or inhibition of cell respiration and to what extent cyclohexenone and
cyclohexanedione derived ET-CORMs differ in their ability to counteract TNF-α mediated inﬂammation.
Irrespective of the formulation (DMSO or cyclodextrin), toxicity in HUVEC was signiﬁcantly higher for
ET-CORMs bearing the ester functionality at the outer (rac-4), as compared to the inner (rac-1) position
of the cyclohexenone moiety. This was paralleled by an increased CO release from the former ET-CORM.
Toxicity was not mediated via iron as EC50 values for rac-4 were signiﬁcantly lower than for FeCl2 or
FeCl3 and were not inﬂuenced by iron chelation. ATP depletion preceded toxicity suggesting impaired
cell respiration as putative cause for cell death. In long-term HUVEC cultures inhibition of VCAM-1
expression by rac-1 waned in time, while for the cyclohexanedione derived rac-8 inhibition seems to
increase. NFκB was inhibited by both rac-1 and rac-8 independent of IκBα degradation. Both ET-CORMs
activated Nrf-2 and consequently induced the expression of HO-1.
This study further provides a rational framework for designing acyloxydiene–Fe(CO)3 complexes as
ET-CORMs with differential CO release and biological activities. We also provide a better understanding
of how these complexes affect cell-biology in mechanistic terms.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
Carbon monoxide is endogenously produced in mammalian
cells through the action of highly conserved haem oxygenase
enzymes [1,2], which catalyse the rate-limiting step in degradation
of haem to biliverdin, iron and carbon monoxide (CO) [3–6]. The
CO system has emerged in recent years as an important key
component in cell physiology and pathophysiology. Based on the
cytoprotective properties of this system, the therapeutic potential
of CO has been extensively explored in a variety of in vitro and
in vivo models [7]. Yet implementation of CO in clinical praxis is
hampered by the fact that CO is also a poisonous gas causing
intoxication when used at critical concentrations [8,9]. CO there-
fore needs to be applied in a controllable fashion to avoid
unwarranted side effects.
While CO inhalation was the foremost application route in the
early days, the use of so called CO-releasing molecules (CORMs)
has become more prominent in recent years. The advantage being
that the latter seems not to interfere with the oxygen carrying
capacity of haemoglobin when used in vivo [7]. Conﬂicting data in
rodents and the lack of a beneﬁcial effect of CO inhalation in
human volunteers on systemic inﬂammation [8,9] also questions
whether inhalation is the most effective route for CO delivery.
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Initiated by the pioneering work of Motterlini et al. [10], a
variety of different CORMs have subsequently been developed,
each of which has different biochemical properties, release rates
and stability [10–12]. Most of these either spontaneously release
CO when dissolved in aqueous solutions or require special physical
or chemical stimuli to favour CO dissociation from these com-
plexes [13–17]. It should be noted that CO delivery by these CORMs
occurs via passive diffusion over the cell membrane and hence
might require higher concentrations of the complexes to obtain
sufﬁcient intracellular levels of CO in cells or tissue as compared to
devices that allow direct intracellular CO delivery. Intracellular CO
delivery can be obtained by the use of enzyme-triggered CORMs
(ET-CORMs) [18,19]. We have recently shown that this group of
CORMs are able to release CO in an esterase dependent manner
and that their biological properties strongly depend on their
chemical structure, more speciﬁcally on the mother compound
from which they derive and the type and position of the ester
functionality that they harbour [20]. Because also cell-speciﬁc
differences in biological activity for the various ET-CORMs were
observed, ET-CORMs may pave the way towards development of
cell or tissue speciﬁc CO delivery. Although at present it is not clear
which of the intracellular esterase enzymes are able to hyrdolyse
ET-CORM, quantitative and or qualitative differences in the expres-
sion of the enzymes in different cell types might underlie cell
speciﬁc differences in the biological activity of ET-CORMs. ET-
CORMs have been tested in RAW267.4 cells, human umbilical vein
endothelial cells (HUVEC) and renal proximal tubular epithelial
cells (PTEC) for their toxicity, inhibition of iNOS, protection against
cold-inﬂicted cell injury and their propensity to inhibit VCAM-1
expression [18,20]. Even though we have previously demonstrated
that the biological activity largely depends on the chemical
structure of ET-CORMs it is unclear how structural differences
inﬂuence cellular up-take and CO-release, and how this in turn
inﬂuences the biological activity of ET-CORMs. It has also not been
addressed to what extent structurally different ET-CORMs behave
similar with respect to their biological activity when tested in a
long-term treatment setting. In the present study we therefore
further evaluated in a more detailed manner the properties of two
cyclohexenone-derived ET-CORMs, i.e. rac-1 and rac-4, and one
derived from cyclohexanedione (rac-8). Since rac-1 and rac-4 only
differ in the position of the ester functionality, being either at the
inner (rac-1) or outer position (rac-4), we ﬁrst assessed if differ-
ences in cytotoxicity between these ET-CORMs were reﬂected by
differences in CO release and if toxicity was mediated through the
concomitant release of iron or inhibition of cell respiration.
Secondly we assessed if the cyclohexenone and cyclohexanedione
derived ET-CORMs (rac-1 and rac-8 respectively) differ in their
propensity to inhibit VCAM-1 expression in long term cultures, if
the mother compound itself contributes to this, and if activation
and inhibition of putative transcription factors for regulation of
VCAM-1 expression are involved.
Materials and methods
Reagents
Reagents were obtained from the following sources: endothe-
lial cell culture medium (Provitro, Berlin, Germany), PBS, trypsin
solution, ethanol (GIBCO, Invitrogen, NY, USA), FBS Gold (PAA
Laboratories GmbH, Pasching, Austria), bovine serum albumin
(SERVA, Heidelberg, Germany), 2,20-pyridyl (2,2-DPD), β-mercap-
toethanol, ethidium bromide, EDTA solution, DMSO, Tween 20,
phosphatase inhibitor cocktail 2, collagenase, HEPES, Triton X-100,
DTT, sodium deoxycholate, Tris-base, ammonium persulphate,
SDS, TEMED, glycine, MTT, hexadimethrine bromide, acrylamide
40%, gelatine (Sigma, Taufkirchen, Germany), protease inhibitor
cocktail, ﬁrst strand cDNA synthesis Kit (Roche Diagnostic, Man-
nheim, Germany), Dual-Glo Luciferase Assay System (Promega,
Mannheim, Germany), Coomassie protein assay reagent (Pierce,
Rockford, IL, USA), Trizol (Invitrogen, Carlsbad, CA, USA), chloro-
form, isopropanol, tetrahydrofuran (Merck, Darmstadt, Germany),
deferoxamin (Roche Diagnostics, Mannheim, Germany), anti-
VCAM-1 (Cell Signalling, Boston, USA), anti-HO-1 (Enzo, Lörrach,
Germany), anti-β-actin (Sigma, Taufkirchen, Germany), Cignal
Lenti NFκB/Nrf2/positive control Reporter (luc) kit (Qiagen, Düs-
seldorf, Germany), Lysis Buffer 5x (Promega, Mannheim, Ger-
many). Secondary antibodies conjugated with horseradish
peroxidase and anti-IκΒa were purchased from Santa Cruz Bio-
technology (Heidelberg, Germany). Chemiluminescence reagent
was purchased from PerkinElmer LAS Inc. (Boston, MA, USA).
Cell culture
Human umbilical vein endothelial cells (HUVEC) were pur-
chased from Promo Cell, Heidelberg, Germany and cultured in
basal endothelial medium supplemented with 10% foetal bovine
serum (FBS), essential growth factors and antibiotics. Cultures
were maintained at 37 1C in a 5% CO2-humidiﬁed atmosphere and
experiments were conducted on cells in passages 4–6 at approxi-
mately 80–90% conﬂuence.
Synthesis
Acycloxydiene complexes (ET-CORMs) rac-1, rac-4 and rac-8
were synthesized and characterized as described previously
[19,20]. Esterase-triggered CO release was shown for all complexes
using the myoglobin assay and headspace gas chromatography
(GC). The parent ligands of the ET-CORMs used, i.e. 2-
cyclohexenone (L1), 1,3-cyclohexanedione (L2) and compound L3
(formally derived from mono-hydrolysis and decomplexation of
rac-8) were included to assess whether the biological activity was
mediated via CO release or via the organic by-products of ET-
CORM cleavage. The chemical structures and annotation of the
compounds used in this study are shown in Fig. 1.
In cell culture experiments rac-1 and rac-4 were used in
different formulations, either dissolved in DMSO or prepared as
randomly methylated-beta-cyclodextrin (RAMEB) complexes. For
the latter 2.4mg (8.75 mmol) of rac-1 or 2.8mg (10 mmol) rac-4
were added to a water solution of 41.25mM (or 40mM, respec-
tively) of RAMEB. The formation of complexes was achieved by
treating samples in an ultrasonic bath at 80 1C for 30min.
“CO probe 1” (COP-1) was synthesized as reported [21] and was
used to assess if ET-CORM RAMEB complexes were still able to
release CO. To this end, COP-1 (10 μΜ), the ET-CORM/RAMEB
complexes (RAMEB@rac-1 and RAMEB@rac-4) (100 mM for both)
and pig liver esterase (3 U/ml) were incubated in 96-well plates for
various time points. In some experiments pig liver esterase was
exchanged for cell lysates from HUVEC (10 mg/ml) as an esterase
source. Cell lysates were prepared by repeated cycles of freeze
thawing in PBS. In all experiments controls were included by
omitting pig liver esterase or cell lysate. Fluorescence intensity
was measured at an excitation/ emission-wavelength of 475/510
nm. For each condition the ﬂuorescence intensity of the controls
was subtracted.
Cell toxicity
HUVEC were cultured in 96-well plates until conﬂuence and
subsequently treated for the indicated time periods with different
concentrations of rac-1 or rac-4 either dissolved in DMSO or as
RAMEB complex. In some experiments, HUVEC were treated for
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24 h with serial dilutions of FeCl2 or FeCl3 or rac-4 (100 mM) in the
presence or absence of deferoxamin (80 mM) or 2,2-DPD (100 mM).
Cell toxicity was assessed by MTT (i.e. 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide). At the indicated times, 10 m
l of 5 mg/ml MTT solution in distilled water were added to each
well for 4 h. Hereafter 100 ml of solubilization solution (10% SDS in
0.01M HCl) were added in each well to dissolve the formazan
crystals. Next day absorbance was measured at 550 nm with a
reference wavelength 690 nm. Cell viability was expressed as %
viable cells relative to the untreated cells. All experimental condi-
tions were tested in triplicate in at least 4 different experiments.
Intracellular ATP measurement
Cells were cultured in 24-well plates and upon conﬂuence
treated with different concentrations of rac-1 or rac-4. Depending
on the speciﬁc experiment 200 ml of lysis buffer (100mM Tris, 4
mM EDTA, pH 7.7) was added to each well after 15 and 60min or
after 24 h of treatment. Lysates were collected and ATP concentra-
tions were assessed directly hereafter using a commercially avail-
able ATP-driven luciferase assay according to the manufacturer’s
instruction (Roche Diagnostics, Mannheim, Germany). All experi-
mental conditions were tested in triplicates in at least 3 different
experiments.
Protein extraction and Western blot analysis
HUVEC were resuspended in lysis buffer (10mM Tris–HCl, 150
mM NaCl, 5mM EDTA, 1% Triton X-100, 0.5% sodium deoxycholate,
1 mM dithiothreitol (DTT), proteinase inhibitor cocktail and phos-
phatase inhibitor). Protein concentrations were measured using
Coomassie-Reagent (Pierce, Rockford, USA). Samples (20 mg protein
extract) were heated to 95 1C for 5min, loaded and separated on
10% SDS-polyacrylamide gels followed by semi-dry blotting onto
PVDF membranes (Roche, Mannheim, Germany). The membranes
were incubated with 5% w/v non-fat dry milk or bovine serum
albumin in TBS/Tween 0.1% to block unspeciﬁc background staining
and hereafter incubated overnight at 4 1C with speciﬁc polyclonal
antibodies, depending on the experiment that was performed.
Subsequently, the membranes were thoroughly washed with TBS-
Tween 0.1% and incubated with the appropriate horseradish per-
oxidase conjugated secondary antibody, followed by ﬁve times
wash in TBS/Tween 0.1%. Proteins were visualized using enhanced
chemoluminescence technology, according to the manufacturer’s
instructions (Pierce, Rockford, IL, USA). To conﬁrm equal protein
loading, membranes were stripped and re-probed with monoclonal
anti-β-actin antibody.
Reporter assays
HUVEC were grown in 96-well plates and transduced with
commercially available lentiviral particles containing an inducible
NFκB or Nrf2 luciferase reporter. To control for transduction
efﬁciency for each condition HUVEC were also transduced with
lentiviral particles containing a constitutively expressed luciferase
construct. Transduction and luciferase activity measurements
were performed as recommended by the manufacturer.
RNA isolation, PCR and RNA stability
Total RNA was isolated as described above. 1 mg of total RNA
was reverse-transcribed into cDNA using the 1st Strand cDNA
Synthesis Kit. cDNA was diluted in 20 ml DEPC-treated water and
stored at 20 1C until use. qPCR was performed on an ABI-Prism
Fig. 1. Chemical structure of the compounds used in the study. The two cyclohexenone-derived ET-CORMs, i.e. rac-1 and rac-4, and the one derived from cyclohexanedione
(rac-8) are depicted. The corresponding hydrolysis products, i.e. enones, of rac-1 and rac-4 (L1) and of rac-8 (L2 and L3) were used to dissect if the hydrolysis products are
partly underlying the biological activity of ET-CORMs.
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7700 sequence detection system using TaqMan universal PCR
master mix No AmpErase UNG (part no. 4324018). The following
TaqMan assays were used: hmxo1 (part no. Hs01110250) and
GAPDH (part no. Hs02758991_g1). Samples were run under the
following conditions: initial denaturation for 10min at 95 1C
followed by 40 cycles of 15 s at 95 1C and 1min at 60 1C. The
levels of gene expression in each sample were determined with
the comparative cycle threshold method. PCR efﬁciency was
assessed from the slopes of the standard curves and was found
to be between 90% and 100%. Linearity of the assay could be
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demonstrated by serial dilution of all standards and cDNA. All
samples were normalized for an equal expression of GAPDH.
Statistical analysis
Data is expressed as the mean7standard deviation (SD) from
at least three independent experiments. Statistical signiﬁcance
was assessed by One-way-ANOVA, and a P-value of Po0.05 was
considered as signiﬁcant. GraphPad Prism was used for calculation
of EC50 values and curve ﬁtting.
Results
CO release, toxicity and intracellular ATP concentrations
Although the cyclohexenone derived ET-CORMs rac-1 and rac-4 (Fig. 1) display
a minor structural difference, i.e. the position of the ester functionality, they
strongly differ with respect to cytotoxicity [20]. Because cellular uptake of
cyclodextrin-formulated compounds predominantly depends on structural entities
of the cyclodextrin polymer rather than that of the compound itself, rac-1 and rac-4
were prepared as such RAMEB@rac-1 and RAMEB@rac-4 respectively, to assess if
the difference in cytotoxicity is caused by quantitative differences in cellular uptake
or CO release. CO was still released from the cyclodextrin formulated compounds,
as demonstrated by a time dependent increase in ﬂuorescence intensity when COP-
1 was incubated with RAMEB@rac-1 and RAMEB@rac-4 in the presence of pig liver
esterase or lysates of HUVEC as the esterase source (Fig. 2a). CO release in this assay
was signiﬁcantly higher for RAMEB@rac-4 as compared to RAMEB@rac-1 and was
more pronounced when lysates from HUVEC were used. When HUVEC were
cultured for 24 h with different concentrations of rac-1 and rac-4, either dissolved
in DMSO or used as cyclodextrin formulation, rac-4 was consistently more toxic
compared to rac-1 irrespective of the formulation (EC50 [mM] rac-1 vs. rac-4:
448.9750.23 vs. 8.271.5, EC50 [mM] RAMEB@rac-1 vs. RAMEB@rac-4: 457.378.23
vs. 7.2271.12) (Fig. 2b). Based on the notion that cellular uptake of the
cyclodextrin-formulated RAMEB@rac-4 and RAMEB@rac-1 is equal, our data
indicate that RAMEB@rac-4 is signiﬁcantly more toxic as a consequence of a higher
CO release as compared to RAMEB@rac-1.
Cell toxicity was also observed when HUVEC were incubated with FeCl2 or
FeCl3 (Fig. 2 c, graph to the left), indicating a potential deleterious role for the
concomitantly released iron upon ET-CORM hydrolysis. However, EC50 values for
rac-4 were signiﬁcantly lower compared to FeCl2 or FeCl3 (EC50 FeCl3 vs. rac-4,
120 vs. 8.271.5 [mM]) and were neither inﬂuenced by deferoxamin (Fig. 2c,
graph to the right) nor by the more cell membrane permeable 2,20-dipyridyl (2,2-
DPD) iron chelator (data not shown). Interestingly, intracellular ATP concentrations
were slightly increased at low concentrations of either rac-1 and rac-4, while at
high concentrations intracellular ATP strongly diminished in HUVEC that were
treated with rac-4 but not with rac-1 (Fig. 2d, graph to the left). When 100 mM of
rac-4 was added to HUVEC, ATP concentrations already diminished within 15min
(Fig. 2d, graph to the right). These data indicate that cytotoxicity of ET-CORMs is
likely attributed to CO release and thus impairment of mitochondrial respiration.
VCAM-1 inhibition and long term ET-CORM treatment
We have previously reported that rac-1 and rac-8 inhibit TNFα-mediated
VCAM-1 expression [20]. Also rac-4 inhibits VCAM-1 at low non-toxic concentra-
tions, i.e. [rac-4]r3 mM (Fig. 3a). We performed a more detailed analysis of VCAM-
1 inhibition and cell toxicity in long-term experiments only for rac-1 and rac-8,
because they display comparable levels of toxicities and the structural difference
between rac-1 and rac-8 is much larger as compared to rac-1 and rac-4. At 100 mM,
cell viability clearly decreased over a time period of 3 days when HUVEC were
cultured in the presence of either rac-1 or rac-8 (Fig. 3b). Since at 50 mM cell
viability remained above 95% throughout the culture period, in all long-term
cultures for VCAM-1 analysis ET-CORM concentrations were 50 mM or lower. While
inhibition of VCAM-1 expression by rac-1 slightly waned in time, VCAM-1
inhibition by rac-8 seems to increase (Fig. 3c). Inhibition of VCAM-1 expression
was also observed for 2-cyclohexenone (L1), but not for 1,3-cyclohexanedione (L2).
To further substantiate that in long-term cultures the inhibitory effect on VCAM-1
expression is much larger for rac-8 as compared to rac-1, HUVEC were cultured for
5 days in the presence of 25 or 12.5 mM of either rac-1 or rac-8 (Fig. 3d, graph to the
right). Cell toxicity was not observed under these concentrations (Fig. 3d, graph to
the left). VCAM-1 expression was inhibited by both compounds in a dose-
dependent manner, yet, rac-8 was clearly more effective as at both concentrations
the inhibitory effect was more pronounced for rac-8. The propensity of rac-1 and
rac-8 to down-regulate VCAM-1 expression was also present when HUVEC were
stimulated with TNFα one day prior to the addition of these ET-CORMs (Fig. 3e and
f panels to the left). However, down-regulation of VCAM-1 expression required the
continuous presence of ET-CORM, as VCAM-1 reappeared upon removal of the ET-
CORM (Fig. 3e and f panels to the right). In keeping with the notion that for
inhibition of VCAM-1 CO needs to be continuously present, our data thus indicate
that the difference in kinetic of VCAM-1 inhibition between rac-1 and rac-8 may
reﬂect differences in the amount of intracellular CO.
Inhibition of NFκB and activation of Nrf-2
In line with inhibition of TNFα-mediated VCAM-1 expression it was found that
both rac-1 and rac-8 inhibit NFκB activation as demonstrated by reporter assay.
Also 2-cyclohexenone (L1), but not 1,3-cyclohexanedione (L2), was able to inhibit
NFκB (Fig. 4a). Inhibition of NFκB was not caused by impaired IκBα degradation, in
fact, reappearance of IκBα in the cytoplasm was consistently found to be slightly
retarded for both ET-CORMs (Fig. 4b). Apart from inhibition of NFκB we also
observed a signiﬁcant activation of Nrf-2 for both ET-CORMs (Fig. 5a), which was
paralleled by the induction of HO-1 at the mRNA- and protein level (Fig. 5b and c).
Similar as observed for NFκB, only the hydrolysis product of rac-1 but not of rac-8,
affected Nrf-2 activation and consequently HO-1 expression.
4. Discussion
The biological activity of ET-CORMs strongly depends on their
design. With respect to the 2-cyclohexenone (L1) derived ET-CORMs
the position of the ester functionality seems to be of critical
importance for the CO release behaviour and hence for the efﬁcacy
to mediate biological activity. In general, CO release from ET-CORMs
is a two-step process in which ﬁrst the ester functional group is
hydrolysed followed by oxidation of the resulting dienol-Fe(CO)3
moiety to liberate carbon monoxide, Fe-ions and the corresponding
cyclohexenone ligand [19]. As rac-1 and rac-4 both contain an
acetate ester as the functional group, it seems unlikely that the
differences in their biological activity only result from differences in
the hydrolysis efﬁciency. We therefore assume that the different
biological activity reﬂects the ease by which the dienol-Fe(CO)3
intermediates derived from rac-1 and rac-4 are oxidized. As
separate mechanistic studies (S. Romanski, Dissertation Universität
zu Köln, 2012) indicate, the oxidative (CO realizing) step occurs
Fig. 2. (a) CO release from rac-1 and rac-4 in cyclodextrin formulation RAMEB@rac-1 and RAMEB@rac-4 respectively was assessed by measuring COP-1 ﬂuorescence
intensity. To this end, COP-1 (10 μΜ), RAMEB@rac-1 and RAMEB@rac-4 (100 mM for both) and pig liver esterase (3 U/ml) (graph to the left) or cell lysates from HUVEC
(10 mg/ml) (graph to the right) were incubated in 96-well plates for various timepoints. In all experiments controls were included by omitting pig liver esterase or cell lysate.
Fluorescence intensity of the controls was subtracted from the ﬂuorescence intensity of each condition. The results of three independent experiments are depicted as mean
ﬂuorescence intensity in arbitrary units7SD, nPo0.05, nnPo0.01. (b) HUVEC were grown in 96-well plates until conﬂuence and subsequently stimulated for 24 h with
different concentrations (0–200 mM) of rac-1, or rac-4 either dissolved in DMSO (graph to the left) or as cyclodextrin formulation RAMEB@rac-1 and RAMEB@rac-4 (graph to
the right). Toxicity was assessed by MTT assay, each concentration was tested in triplicate in all experiments. The results of 3 independent experiments are expressed as
mean% of cell viability7SD, relative to the untreated HUVEC. The corresponding EC50 [mM] were rac-1 vs. rac-4: 448.9750.23 vs. 8.271.5, EC50 [mM] RAMEB@rac-1 vs.
RAMEB@rac-4: 457.378.23 vs. 7.2271.12. (c) Serial dilutions of FeCl2 (open circles, dotted line) or FeCl3 (closed circles) and rac-4 (closed squares) were added to HUVEC
grown in 96-well plates and toxicity was measured similar as described above. To test if iron-mediated toxicity was abrogated in the presence of deferoxamine, cells were
stimulated with 125 mM of FeCl2, FeCl3 or rac-4 in the presence (ﬁlled bars) or absence (open bars) of deferoxamine (80 mM) (graph to the left). The plates were incubated for
24 h and cell viability was assessed by MTT assay as described. The results of 3 independent experiments are expressed as mean% of cell viability7SD, relative to the
untreated HUVEC. (d) HUVEC were grown in 24-well plates until conﬂuence, treated with rac-4 or rac-1 for 24 h. Subsequently intracellular ATP was measured (graph to the
left). In separate experiments, 50 mM of rac-4 was added to HUVEC and ATP was measured at 0, 15 and 60min after addition of ET-CORM (graph to the right). ATP was
measured using an ATP-driven luciferase assay as described in the methods section. The results of 4 independent experiments are expressed as mean relative light units
(RLU)7SD. In all experiments each condition was tested in triplicates. nPo0.05, nnPo0.01 vs. the untreated HUVEC.
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much easier for rac-4 as compared to rac-1. Indeed we could
demonstrate that CO release from rac-4 is signiﬁcantly higher as
compared to rac-1. These data are in line with previous ﬁndings
using the myoglobin assay and headspace gas chromatography
[19,20]. In keeping with the fact that esterase-triggered disintegra-
tion of the rac-4 complex occurs faster than for rac-1, as indicated
by CO release from these complexes, this might explain the large
difference in toxicity between the two ET-CORMs. A differential
Fig. 3. (a) To demonstrate that rac-4 also inhibits VCAM-1 expression at low-non-toxic concentrations, HUVEC were stimulated with TNF-α for 24 h in the presence or
absence of different concentrations of rac-4. Note that at these concentrations inhibition of VCAM-1 occurs. VCAM-1 expression was assessed by Western blotting, β-actin
was used as loading control. (b) HUVEC were grown in 96-well plates until conﬂuency and subsequently incubated with serial dilutions (0–400 mM) of rac-1 (graph to the
left) or rac-8 (graph to the right). Cell viability was assessed at different time points (24, 48 and 72 h) by MTT as described. All experimental conditions were tested in
triplicates in at least 5 independent experiments. nnPo0.01 with respect to untreated cells. (c) Cells were stimulated with TNF-α for the indicated time periods in the
presence or absence of 50 mM of rac-1, L1 (panels to the left), rac-8 or L2 (panels to the right). Compound L3 (Fig. 1) as an additional possible hydrolysis/disintegration
product of rac-8 was tested in various experiments and gave similar results as L2 (data not shown). Cells that were not stimulated with TNF-α served as control. VCAM-1
expression was assessed byWestern blotting; β-actin was used as loading control. (d) Cells were stimulated with TNF-α for 5 days in the presence or absence of 25 or 12.5 mM
of rac-1 or rac-8. Cells that were not stimulated with TNF-α served as control. VCAM-1 expression was assessed by Western blotting; β-actin was used as loading control
(panel to the left). HUVEC were grown in 96-well plates until conﬂuency and subsequently incubated with 12.5 or 25 mM of rac-1 or rac-8. Cell viability was assessed by MTT
assay (panel to the right) and was expressed as % viable cells relative to the untreated cells. All experimental conditions were tested in triplicates in at least 5 independent
experiments. (e, f) HUVEC were stimulated for 24 h with TNF-α (10 ng/ml). Hereafter, 50 mM of rac-1 (e) or rac-8 (f) was added without changing the medium and the cells
were cultured for additional 24 h. VCAM-1 expression was assessed at 24 h of TNF-α stimulation to assure that it was present before addition of rac-1 or rac-8 and after 48 h
to test if addition of rac-1 or rac-8was still able to affect VCAM-1 expression. Cells that did not receive rac-1/rac-8 served as control. Cells that were not stimulated with TNF-
α were included to demonstrate VCAM-1 induction (panels to the left). In separate experiments cells were stimulated for 24 h with TNF-α (10 ng/ml) in the presence or
absence of 50 mM of rac-1 or rac-8. After 24 h in separate wells the medium was exchanged for medium that only contained TNF-α (10 ng/ml) (removal) or medium that
contained both TNF-α and rac-1 or rac-8 (presence) and cells were allowed to grow for additional 24 h. VCAM-1 expression was assessed at 24 h to demonstrate that rac-1
inhibits VCAM-1 expression and after 48 h to demonstrate that VCAM-1 expression reappeared after removal of rac-1 and rac-8 as well. Cell cultures grown for 48 h in the
continuous presence of TNF-α (c) and cells that were not stimulated with TNF-α were also included (panels to the right). For (c) to (f) data of a representative experiment are
shown. At least 4 independent experiments have been performed with essentially the same results.
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cellular uptake of rac-1 and rac-4 is most likely not underlying the
differences in cytotoxicity as these differences remained even
though both compounds were made as cyclodextrin formulation.
The chemical properties of RAMEB, but not of the ET-CORMs, are
expected to mainly determine the cellular uptake of such a
formulation. In contrast to the mono-acetate rac-1 derived from
2-cyclohexenone (L1), complex rac-8 (derived from 1,3-cyclohex-
anedione (L2) and containing two pivalate ester functionalities)
displays a signiﬁcantly higher toxicity, as previously reported
[18,20]. The hydrolysis of the sterically demanding pivalate ester
(rac-8) is expected to be comparably slow as it has been demon-
strated for other ester-containing prodrugs [22,23]. Hence this may
explain why the levels of toxicity between rac-1 and rac-8 were
comparable even if the former contains an easier hydrolysable
acetate ester.
Toxicity was not mediated by the organic ligands liberated from
the ET-CORMs upon ester cleavage and oxidative disintegration.
Thus, no toxicity was observed for 2-cyclohexenone (L1), 1,3-
cyclohexanedione (L2) or for the enol pivalate (L3) expected to
be formed from rac-8 (Fig. 1) (data not shown). Also the Fe-ions,
which are concomitantly released upon hydolysis/oxidation of the
ET-CORMs, do not seem to make a large contribution to cell
toxicity for the following reasons. Firstly, toxicity for FeCl2 or FeCl3
was observed only at much higher concentration as compared to
rac-4 and, secondly, FeCl2/FeCl3-mediated toxicity was abrogated
by iron chelators, whereas this was not observed for rac-4. It thus
seems that the toxicity of ET-CORMs primarily depends on the
speed or extent of CO release, which may impede cell respiration
via inhibition of cytochrome c oxidase [24]. The ﬁnding that
impaired ATP production proceeds cell death further supports
the assumption that toxicity of ET-CORMs might be causally linked
to cell respiration.
Interestingly, at low concentrations ET-CORMs signiﬁcantly
increased ATP levels. Previous studies also have reported on
increased ATP production when using low CO concentrations
either as CO gas or CORM-3. It seems that this is mediated by
activation of soluble guanyl cyclase (sGC) [25,26] and that this is
accompanied by increased speciﬁc oxygen consumption (state
2 respiration) [27,28]. In contrast, high CO concentration can
impair cell respiration.
The inhibitory properties of CO on the expression of adhesion
molecules or its anti-inﬂammatory action in general have unam-
biguously been demonstrated in vitro and in vivo [29–32]. Like-
wise the induction of HO-1 by CO and its contribution to inhibition
of inﬂammatory mediators has been extensively discussed [33,34].
In line with these published data, it seems that ET-CORMs do not
differ in this respect as they are able to inhibit VCAM-1 and induce
HO-1 [20]. As suggested in the present study, ET-CORMs may
mediate these effects through their propensity to inhibit NFκB in
an IκBα independent manner and to activate Nrf-2. We also show
evidence that ET-CORMs can down-regulate existing VCAM-1
expression and that inhibition is reversible, as it is no longer
observed once ET-CORMs are removed from the cultured medium.
Even though TNFα-mediated VCAM-1 was inhibited by both 2-
cyclohexenone (L1) and 1,3-cyclohexadione (L2) derived ET-CORMs,
two major differences were found: ﬁrstly, inhibition of VCAM-1
Fig. 3. (continued)
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Fig. 4. (a) HUVEC were transduced by lentiviral particle with an inducible promoter construct containing dual NFκB-consensus motifs and with a constitutively active CMV-driven
promoter construct both cloned behind luciferase cDNA. Two days after transduction the cells were stimulated for 24h with TNF-α (10 ng/ml) in the presence of absence of 50 μΜ
rac-1, rac-8, L1 (cyclohexenone) or L2 (cyclohexanedione), respectively. Hereafter luciferase expression was measured as described in the methods section. Inducible luciferase
expressionwas normalized for constitutively expressed luciferase to control for differences in transduction efﬁciency. The data of 4 independent experiments are expressed as mean
fold increase7SD relative to TNF-α stimulated cells. ns: not signiﬁcant, nnPo0.01 vs. TNF-α stimulated cells. (b) HUVEC were treated for 4 h with 50 mM rac-1 or rac-8 before
stimulation with TNF-α. ET-CORMs were present during stimulation. Cell lysates were directly prepared after 15, 30, 45 and 60min of TNF-α stimulation and subjected to
electrophoresis and Western blotting for analysis of ΙκBα expression and β-actin as loading control. Cells that were not stimulated with TNF-α were included to assess constitutive
levels of ΙκBα. The data of a representative experiment is depicted. At least 4 independent experiments have been performed with essentially the same results.
Fig. 5. (a) HUVEC were transduced by lentiviral particle with an inducible promoter construct containing dual ARE motifs and with a constitutively active CMV-driven
promoter construct both cloned behind luciferase cDNA. Two days after transduction the cells were treated for 24 h with 50 μΜ rac-1, rac-8, L1 (cyclohexenone) or L2
(cyclohexanedione) respectively. Hereafter, luciferase expression was measured as described in the methods section. Inducible luciferase expression was normalized for
constitutively expressed luciferase to control for differences in transduction efﬁciency. The data of 4 independent experiments are expressed as mean fold increase7SD
relative to untreated cells (medium). ns: not signiﬁcant, nnPo0.01, vs. untreated cells (medium). (b) HUVEC were treated for 24 h with 50 mM rac-1 or rac-8 or left untreated.
Hereafter, total RNA was isolated and the expression of HO-1 (hmxo1) was quantitated by qPCR and normalized for equal GAPDH expression. Normalized hmxo1 mRNA
levels are expressed as mean fold increase7SD relative to untreated cells (medium), nnPo0.01, vs. untreated control. (c) HUVEC were treated for 24 h with the indicated
concentrations of rac-1, L1, rac-8 or L2. Hereafter, proteins extracts were made and HO-1 expression was assessed by western blotting, β-actin was used as loading control.
The data of a representative experiment are depicted. At least 4 independent experiments have been performed with essentially the same results.
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expression and induction of HO-1 was also observed for L1 itself but
not L2, and parallel the ﬁndings of NFκB inhibition and Nrf-2
activation. Secondly, it seemed that VCAM-1 inhibition by the L2-
derived rac-8 was slower and lasted longer as compared to rac-1.
This might reﬂect a slower CO release for rac-8 as a consequence of
its higher resistance to hydrolysis. Due to a high background
ﬂuorescence of COP-1 labelled HUVEC we were not able to convin-
cingly conﬁrm that intracellular CO release by rac-8 is indeed slower
as compared to rac-1. Therefore better CO probes for monitoring
intracellular CO levels are required to address this issue. Alternatively,
the differences of VCAM-1 inhibition kinetics might also be explained
by the fact that L1 itself contributes to VCAM-1 inhibition, while L2
and L3 do not.
The growing awareness that CO not only is a poisonous gas but
also displays a variety of beneﬁts and the ﬁnding that CO as
therapeutic gas has intrinsic limitations, have signiﬁcantly paved
the way for developing pro-drugs acting as CO-releasing molecules
[10–12]. Pre-clinical studies with the most widely used CORMs, i.e.
CORM2A and CORM-3, have clearly demonstrated their therapeu-
tic efﬁcacy in settings of ﬁbrosis [35], inﬂammation [32,36–38],
vascular dysfunction [35,39] and oxidative damage [39]. Yet it
should be underscored that these CORMs predominantly deliver
CO to cells and tissue via passive diffusion once CO is released
rather than a direct intracellularly delivery of CO. This is in strong
contrast to ET-CORMs which deliver CO only intracellularly
through the action of esterases. ET-CORMs may offer certain
advantages over the existing CORMs as lower concentrations of
ET-CORMs might be required for similar biological activities. Even
though a direct comparison between, e.g. CORM-3 and ET-CORMs
was not performed, previously published data have shown that 1
mM of CORM-3 was required for complete inhibition of TNFα-
mediated VCAM-1 expression [32] while in the current study
complete inhibition was observed for rac-1 at 50 mM (Fig. 3) and
for rac-4 at 3 mM (Fig. 3a). Secondly, ET-CORMs may also be
synthesized as bifunctional complexes in which both CO and
hydrolysis by-product may exert synergistic or complementary
biological activities. In fact, this is to a certain extend already
shown for rac-1 and rac-4 in that the hydrolysis product L1 also
contributes to the biological activity of these ET-CORMs. While L1
clearly inhibits VCAM-1 expression, presumably via inhibition of
NFκB, and activates Nrf2, it is conceivable that not all biological
activities displayed by rac-1 and rac-4 can also be mediated by L1.
Indeed, L1 is not able to protect against cold inﬂicted injury while
rac-1 does [20], suggesting not only synergy between CO and L1
but also complementarity. Bifunctional gasotransmitter-based
molecules have also been reported for NO, i.e. naproxcinod, a
derivative of naproxen with a nitroxybutyl ester allowing it to act
as a nitric oxide (NO) donor [40], and for H2S, i.e. ATB-346 and
ATB-337 containing H2Sreleasing moieties on naproxen and
diclofenac respectively [41–43]. Thirdly, ET-CORMs may also be
designed as complexes containing peptide sequences that can be
recognized by cell speciﬁc peptidases, making a cell restricted CO
delivery even more realistic.
In conclusion the present study demonstrates that cyclohex-
enone derived ET-CORMs might be considered as bifunctional
molecules as not only the released CO but also their corresponding
enone contributes to the biological effect tested in this study. This
is in contrast to the cyclohexanedione ET-CORM in which the
corresponding enones do not contribute to the biological activity.
For the two different cyclohexenone derived ET-CORMs the
biological effect seems to depend on the speed or extent of CO
release. Our current data also warrants further in vivo studies to
assess the therapeutic efﬁcacy of ET-CORMs. Although their
chemical design may offer certain advantages over existing CORMs
this needs to be further explored. The question whether bifunc-
tional ET-CORMs and those that may be triggered by cell-speciﬁc
peptidase enzymes can be synthesized with expected biological
activity is intriguing but requires further exploration.
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